Radiotherapy & Oncology
Volume 102, Issue 1 , Pages 10-13 , January 2012

Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial

  • Gudrun Resch

      Affiliations

    • Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Austria
    • Corresponding Author InformationCorresponding author. Address: Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, A-4600 Wels, Austria.
    • ,
  • Alexander De Vries

      Affiliations

    • Department of Radiotherapy and Radio-Oncology, Feldkirch Hospital, Austria
    • ,
  • Dietmar Öfner

      Affiliations

    • Department of Surgery, Paracelsus Private Medical University Salzburg, Austria
    • ,
  • Wolfgang Eisterer

      Affiliations

    • Department of Internal Medicine I, Innsbruck Medical University, Austria
    • ,
  • Hans Rabl

      Affiliations

    • Department of Surgery, Leoben-Eisenerz Hospital, Austria
    • ,
  • Michael Jagoditsch

      Affiliations

    • Department of Surgery, St. Veit Hospital, Austria
    • ,
  • Michael Gnant

      Affiliations

    • Department of Surgery, Medical University of Vienna, Austria
    • ,
  • Josef Thaler

      Affiliations

    • Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Austria
    • ,
  • on behalf of the Austrian Breast and Colorectal Cancer Study Group

Received 20 October 2010 ,Revised 18 May 2011 ,Accepted 5 June 2011.

References 

  1. Sebag-Montefiore D, Bujko K, Valentini V, et al. Rectal cancer multidisciplinary management: evidences and future landscape. Radiother Oncol. 2009;92:145–147
  2. Glimelius B, Oliveira J. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:54–56
  3. Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. Br J Surg. 1999;86:379–384
  4. McFarlane JK, Ryall RP, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–460
  5. Kapiteijn E, Marijnen C, Nagtegaal I, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646
  6. Swedish rectal cancer trial: improved survival with preoperative radiotherapy in respectable rectal cancer. N Engl J Med 1997;336:980–7.
  7. Folkesson J, Birgisson H, Pahlman L, et al. Swedish rectal cancer trail: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–5650
  8. Gerard JP. Radiotherapy in the conservative treatment of rectal cancer. Evidence-based medicine and opinion. Radiother Oncol. 2005;74:227–233
  9. Giralt J, Tabernero J, Navalpotro B, et al. Pre-operative chemotherapy with UFT and leucovorin in patients with advanced rectal cancer: a phase II study. Radiother Oncol. 2009;89:263–269
  10. Klautke G, Küchenmeister U, Foitzik T, et al. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and optimize efficacy measured by pathologic complete response. Radiother Oncol. 2007;85:379–384
  11. Debucquoy A, Roels S, Goethals L, et al. Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer. Radiother Oncol. 2009;93:273–278
  12. Crane CH, Skibber JM, Birnbaum EH, et al. The addition of continuos infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2003;57:84–89
  13. Wiltshire KL, Ward IG, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys. 2006;64:709–716
  14. Bosset J, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123
  15. Gerard J, Bonnetain F, Conroy T, et al. Preoperative radiotherapy + 5 FU/folinic acid in T3–4 rectal cancer: results of the FFCD 9203 randomized trial. J Clin Oncol. 2006;24:4620–4625
  16. Kim DY, Jung KH, Kim TH, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007;67:378–384
  17. Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine vs protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006;66:1378–1383
  18. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiatiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740
  19. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, flurouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  21. Saltz L, Diaz-Rubio E, Scheithauer W, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019
  22. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989;10:1–10
  23. Hermanek P, Wittekind C. The pathologist and the residual tumor (R) classification. Pathol Res Pract. 1994;190:115–123
  24. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123
  25. Gerad J, Bonnetain R, Conroy T, et al. Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-T4 rectal cancers. Results of the FFCD 9203 randomized trial. Eur J Cancer. 2005;3:170
  26. Öfner D, DeVries A, Schaberl-Moser R, et al. Preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with newly diagnosed, primary operable, cT3NxM0, low rectal cancer: a phase II study. Strahlenther Onkol. 2011;187:100–107
  27. Eisterer W, DeVries A, Öfner D, et al. Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03. J Clin Oncol. 2009;27:[Abstract #4109]
  28. Willett C, Duda DG, di Tomaso E, et al. Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020–3026
  29. Willett C, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in recal cancer patients. J Clin Oncol. 2005;23:8136–8139
  30. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:824–830
  31. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843–850
  32. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  33. Hapani S, Sher A, Chu D, Wu S. Increases risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79:27–38

☆ Previous presentation: Abstract published at ASCO GI 2010, # 496.

PII: S0167-8140(11)00319-7

doi: 10.1016/j.radonc.2011.06.008

Radiotherapy & Oncology
Volume 102, Issue 1 , Pages 10-13 , January 2012

Article Tools

* Image Usage & Resolution